GLP-1 & Macular Degeneration Risk in Diabetes
- People with diabetes who use glucagon-like peptide-1 (GLP-1) receptor agonists face a possibly elevated risk of developing neovascular age-related macular degeneration (nAMD), according to a study in JAMA...
- Age-related macular degeneration affects the macula, the central part of the retina, leading to a decline in sharp, detailed vision.
- GLP-1s play a key role in glucose regulation.Recent studies have also pointed to a possible connection between semaglutide, a GLP-1 agonist, and a higher risk of nonatretic anterior...
Diabetic patients using GLP-1 receptor agonists may face double the risk of neovascular age-related macular degeneration (nAMD), a serious cause of vision loss, according to new research. This study,published in JAMA Ophthalmology,analyzed data from over 139,000 individuals aged 66 and older with diabetes,revealing a concerning link between these popular diabetes drugs and eye health. The findings suggest a potential connection between GLP-1s, like semaglutide, and the abnormal growth of blood vessels in the retina. The Canadian study highlights the need for clinicians to be vigilant and calls for more research into the underlying mechanisms. News Directory 3 reports on the latest health developments, so stay informed. Discover what’s next as researchers continue to investigate the long-term effects of these medications on vision.
Diabetes Drugs May Increase Macular Degeneration risk
People with diabetes who use glucagon-like peptide-1 (GLP-1) receptor agonists face a possibly elevated risk of developing neovascular age-related macular degeneration (nAMD), according to a study in JAMA Ophthalmology. The research suggests the risk could be twice as high compared to diabetic individuals not using GLP-1 treatments.
Age-related macular degeneration affects the macula, the central part of the retina, leading to a decline in sharp, detailed vision. nAMD, the more severe form, involves abnormal blood vessel growth and is responsible for a significant portion of vision loss. Symptoms include blurry vision, difficulty with close-up work, blind spots, and distorted lines.
GLP-1s play a key role in glucose regulation.Recent studies have also pointed to a possible connection between semaglutide, a GLP-1 agonist, and a higher risk of nonatretic anterior ischemic optic neuropathy. This has led to the theory that rapid blood sugar reduction from GLP-1s could create a low-oxygen environment in the retina, potentially encouraging abnormal vessel growth, similar to the processes involved in nAMD.
The Canadian study, conducted from January 2020 to November 2023, examined data from over 139,000 individuals aged 66 and older with diabetes. Of those,46,334 were exposed to GLP-1 RAs,primarily semaglutide. The researchers matched these individuals with 92,668 unexposed patients,accounting for factors like socioeconomic status and other health conditions associated with AMD.
The results showed that 0.2% of GLP-1 users developed neovascular AMD, compared to 0.1% of non-users. The study indicated that age and a history of cerebrovascular events also contributed to the risk of neovascular age-related macular degeneration.
The study authors said clinicians should stay informed about potential eye-related complications from GLP-1 RA use. They also encouraged reporting any suspected adverse events to pharmacovigilance systems.
What’s next
Further research is necessary to fully understand the biological mechanisms at play and to carefully weigh the benefits of GLP-1 receptor agonists against potential risks to vision.